Shattuck Labs, Inc. STTK
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Shattuck Labs, Inc. (STTK) is a healthcare company listed in the US with a market value of about $474M. In fiscal year 2025 it had revenue of $1M and net income of -$49M, a net margin of -4880.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -37% a year, a 5-year average ROIC of -46%.
About Shattuck Labs
Shattuck Labs is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $10M in 2019 to $1M in 2025, a decline of about 31.7% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 64% over three years (dilution for shareholders). It spends 3527% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- 3-year revenue growth above 10% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $1M | $6M | $2M | $652000 | $30M | $10M | $10M |
| Net income | -$49M | -$75M | -$87M | -$102M | -$45M | -$37M | -$24M |
| Free cash flow | -$40M | -$61M | -$82M | -$106M | -$65M | -$34M | -$21M |
| EPS (diluted) | $-0.70 | $-1.49 | $-2.05 | $-2.41 | $-1.07 | $-2.36 | $-3.17 |
| Net margin | -4880.9% | -1318.1% | -5268.4% | -15635.7% | -149.8% | -368.5% | -242.6% |
| ROIC | -48.0% | -76.6% | -48.8% | -45.1% | -13.2% | -9.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $15.40, 231% above the current price; targets range from $10.00 to $19.00; the consensus rating is “Strong buy”; expected EPS is $-0.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Shattuck Labs pay a dividend?
Not currently.
Is Shattuck Labs a good stock to buy?
We do not give buy or sell advice. Shattuck Labs scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.